Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoadjuvant Operable Breast Cancer × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 170 Neoplasm Metastasis 23 Neoplasms 18 Ovarian Neoplasms 11 Sarcoma 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Melanoma 6 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Breast Diseases 6 Prostatic Neoplasms 5 Multiple Myeloma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Sarcoma, Ewing 4 Recurrence 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Medulloblastoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Glioblastoma 4 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Osteosarcoma 3 Neuroblastoma 3 Neoplasms by Site 3

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡